Know Cancer

or
forgot password

A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting


Phase 1
18 Years
N/A
Not Enrolling
Both
Breast Neoplasms

Thank you

Trial Information

A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting


Inclusion Criteria:



- Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.

- Candidate for treatment with paclitaxel.

Exclusion Criteria:

- Prior chemotherapy in the advanced disease setting.

- HER2 positive disease unless previously treated with trastuzumab.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety of the combination of SU011248 and paclitaxel

Outcome Time Frame:

9/05-7/07

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A6181073

NCT ID:

NCT00174434

Start Date:

September 2005

Completion Date:

August 2007

Related Keywords:

  • Breast Neoplasms
  • Breast Neoplasms
  • Neoplasms

Name

Location

Pfizer Investigational SiteSpringfield, Illinois  62701-1014
Pfizer Investigational SiteBronx, New York  10461
Pfizer Investigational SiteCarmel, Indiana  46032